Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 26;6(11):e794. doi: 10.1097/HS9.0000000000000794

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Figure 4. — Follow-up of lymphocyte numbers, subset frequencies, and functional characteristics in cHL patients at the end of standard primary treatment and 6 months later. Comparing limited-stage cHL patients at baseline (n = 27) to EoT (n = 25) and FU (n = 25), and advanced-stage cHL patients at baseline (n = 15) to EoT (n = 12) and FU (n = 14). (A) Absolute lymphocyte count (ALC) and absolute numbers of major lymphocyte populations (B cells, T cells, CD4⁺ T cells, CD8⁺ T cells, and CD4/CD8 ratio before and after treatment). (B) Percentages of CD4⁺ T cells that are expressing functional markers (Ki67, CD69, PD-1, and CTLA-4) before and after treatment. (C) The concentration of CCL17/TARC in plasma before and after treatment. Data are depicted as connected dots that indicate the median with error bars that indicate the interquartile range. Plus signs illustrate the P-value of Mann-Whitney tests comparing the respective time points with controls. (D) Percentages of CD8⁺ T cells that are expressing functional markers (Ki67, CD69, PD-1, and CTLA-4) before and after treatment. (E) Absolute numbers of NK cells, CD56^bright NK cells, CD56^dim NK cells, and NK cells that are expressing functional markers (CD69, HLA-DR, NKG2D, and DNAM-1) before and after treatment. Paired data are depicted as connected dots that indicate the median with error bars that indicate the interquartile range. Stars indicate the P-value of a Wilcoxon test comparing the indicated time points. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ADV = advanced-stage; BL = baseline; cHL = classical Hodgkin lymphoma; CTLA = cytotoxic T lymphocyte antigen; DNAM = DNAX accessory molecule; EoT = end of treatment; FU = follow-up 6 months after EoT; LIM = limited-stage; NK = natural killer; NKG2D = NK group 2 member D.